Loading...
 
Translate Register Log In Login with facebookLogin and Register

Vitamin D for elderly 800 to 2000 IU - Osteoporosis Canada - Sept 2010

Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada (summary)

David A. Hanley MD, Ann Cranney MB BCh, Glenville Jones PhD, Susan J. Whiting PhD, William D. Leslie MD;

for the Guidelines Committee of the Scientific Advisory Council of Osteoporosis Canada


Previously published at www.cmaj.ca
CLICK HERE for PDF

The following sections were extracted from PDF - for ease of access in English and other languages

Key points

  • Vitamin D is essential for the prevention of osteoporosis.
  • A serum level of 25-hydroxyvitamin D above 75 nmol/L reflects optimal vitamin D intake or synthesis to consistently improve clinical outcomes such as fracture risk; vitamin D supplementation is needed to achieve this target.
  • Recommended intake for low-risk and younger adults should be increased to 10–25 ?g (400–1000 IU) daily and for high-risk and older adults, to 20–50 ?g (800–2000 IU) daily, with consideration of higher doses (key change from 2002 guideline).
  • For individuals being treated with pharmacologic agents for osteoporosis, vitamin D status should be assessed by serum measurement of 25-hydroxyvitamin D after three months of vitamin D supplementation (key change from 2002 guideline).

Box 1 Assessment of vitamin D

  1. Measurement of 25-hydroxyvitamin D in the serum (with no restrictions on the timing of collection ) is the best indicator of vitamin D sufficiency2 (level 2 evidence).
  2. In the absence of external laboratory proficiency testing, serum 25-hydroxyvitamin D values from different clinical laboratories cannot be assumed to be comparable 8,10 (level 2 evidence).
  3. Monitoring of routine vitamin D supplementation by measurement of serum 25-hydroxyvitamin D is unnecessary (level 4 evidence). Monitoring of high-risk patients and those with osteoporosis should not be performed before three months of standard supplementation (20–50 ?g [800–2000 IU daily) 11 (level 2 evidence). Patients taking daily doses above Health Canada’s “tolerable upper intake level” (currently set at 50 ?g 2000 IU) should undergo monitoring of serum 25- hydroxyvitamin D (level 4 evidence).

Sources of vitamin D

  1. In Canada, some vitamin D is obtained with safe exposure to the sun during the summer months46–48 (level 1 evidence), but exposure to sunlight and dietary intake are insufficient to maintain average serum 25-hydroxyvitamin D concentration above 75 nmol/L throughout the year 11,18,19 (level 2 evidence).
  2. A daily intake of 25 ?g vitamin D3 (1000 IU) — a safe, commonly available dose — will raise the average serum level of 25-hydroxyvitamin D by 15–25 nmol/L 11,21 (level 2 evidence).
  3. The upper level for safe vitamin D3 intake has not been well defined but is probably as high as 250 ?g (10 000 IU) daily 11,22 (level 2 evidence). In clinical practice, supplementation with this dose of vitamin D is rarely required (level 4 evidence).

Effect of supplementation on bone mineral density, fractures and falls

  1. Supplementation with vitamin D3 and calcium increases bone density in postmenopausal women and in men over age 50 years 24,27,28,49 (level 1 evidence).
  2. Vitamin D3 at daily doses of 20 ?g (800 IU), in combination with calcium (1000 mg), reduces the risk of hip and nonvertebral fractures in elderly people living in institutions (level 1 evidence). The evidence for community-dwelling individuals is less strong 50 (level 2 evidence).
  3. There is evidence that supplementation with 20 ?g (800 IU) vitamin D3 daily reduces the risk of falls, particularly from trials with adequate ascertainment of falls 38 (level 2 evidence).

Nontraditional roles of vitamin D

  1. Vitamin D insufficiency has been associated with malignancies40 (especially colorectal cancer 41), diabetes mellitus,45 multiple sclerosis 51 and impaired immune response 44 (level 3 evidence).
  2. The benefits of vitamin D for these nontraditional roles are associated with 25-hydroxyvitamin D levels above 75 nmol/L (30 ng/ml) 21,40 (level 3 evidence).
  • Levels of evidence are explained in detail in the full guideline. 4 In brief, levels of evidence range from very high quality (level 1+, systematic overview or meta-analysis of randomized controlled trials) to very low quality (level 6, case series without controls).

Box 2: Recommendations for vitamin D supplementation

  1. Adequate vitamin D status, in addition to calcium from diet or supplements, is essential for the prevention of osteoporosis (level 1 evidence, grade A recommendation).
  2. Administration of vitamin D and calcium should not be used as the sole treatment for osteoporosis (level 1 evidence, grade A recommendation).
  3. The optimal level of serum 25-hydroxyvitamin D for musculoskeletal benefits is at least 75 nmol/L (30 ng/ml) (level 2 evidence, grade B recommendation).
  4. Laboratories performing 25-hydroxyvitamin D testing should take part in external proficiency surveys and should demonstrate that values reported for shared samples approximate the consensus values reported by others (level 4 evidence, grade D recommendation).
  5. In healthy adults at low risk for vitamin D deficiency (i.e., under age 50, without osteoporosis or conditions affecting vitamin D absorption or action), routine vitamin D supplementation (10–25 ?g 400–1000 IU daily) is recommended. Serum 25-hydroxyvitamin D should not be measured (level 5 evidence, grade D recommendation).
  6. Adults over 50 years of age are at moderate risk for vitamin D deficiency. Supplementation with at least 20–25 ?g (800–1000 IU) of vitamin D3 daily is recommended. To achieve optimal vitamin D status (> 75 nmol/L) (>30 ng/ml) , many individuals may require supplementation at greater than 25 ?g (1000 IU) daily. Doses up to 50 ?g (2000 IU) are safe and do not require monitoring (level 3 evidence, grade C recommendation).
  7. For individuals receiving pharmacologic therapy for osteoporosis, measurement of serum 25-hydroxyvitamin D should follow three to four months of adequate supplementation and should not be repeated if the optimal level is achieved (grade D recommendation).
  8. Measurement of serum 25-hydroxyvitamin D is recommended for individuals with recurrent fractures, bone loss despite osteoporosis treatment or comorbid conditions that affect vitamin D absorption or action (grade D recommendation). Dose requirements above Health Canada’s current tolerable upper intake level (50 ?g 2000 IU) may be needed, in which case monitoring of serum 25-hydroxyvitamin D levels is required (level 4 evidence, grade D recommendation).
  9. Exposure to natural sunlight , when used in moderation (avoiding sunburn) and individualized to the person’s skin type, can contribute to summertime vitamin D sufficiency (level 2 evidence, grade B recommendation).
  10. Research is needed to better define the minimum required daily dose and the optimal dose for musculoskeletal and other health benefits, and to better establish the tolerable upper level for vitamin D supplementation (grade D recommendation).

Competing interests

All authors were members of the Vitamin D Working Group of Osteoporosis Canada.

David A. Hanley has been an investigator in clinical trials, participated in advisory boards or received speaking honoraria from the following companies: Amgen, Merck Frosst Canada, Proctor and Gamble Canada (now Warner-Chilcott), sanofi-aventis, Novartis, NPS Phar- maceuticals, Eli Lilly Canada, Pfizer, Wyeth-Ayerst, Roche, Servier, Abbott Laboratories and Nycomed.

Glenville Jones serves on the scientific advisory board of the not-for-profit Vitamin D External Quality Assessment Scheme. He is also on the advisory board and has received a research grant from Cytochroma Inc. and is a member of the Genzyme speakers’ bureau.

Susan J. Whiting is a member of the International Institute for Nutrition and Bone Health, an educational initiative sponsored by Yoplait. She has received current or recent funding in the form of grants and contracts from the Canadian Institutes of Health Research and the Canadian Foundation for Dietetic Research. She is a nutrition consultant to Osteoporosis Canada. She has presented talks with sponsorship from the Dairy Farmers of Canada, the International Alliance of Dietary/Food Supplement Associations, the Vitamin D Society, GlaxoSmithKline and Amway/Nutrilite.

William D. Leslie has received speaker fees and unrestricted research grants from Merck Frosst Canada Ltd; unrestricted research grants from sanofi-aventis, Procter and Gamble Pharmaceuticals Canada, Novartis, Amgen Pharmaceuticals Canada and Genzyme Canada; and has served on advisory boards for Genzyme Canada, Novartis and Amgen Pharmaceuticals Canada.

Ann Cranney None declared

REFERENCES

1. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and man- agement of osteoporosis in Canada. CMAJ 2002;167(Suppl):S1-34.
2. Institute of Medicine. Dietary reference intakes for calcium, phosphorus, magne- sium, vitamin D and fluoride. Washington (DC): National Academy Press; 1997.
3. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measure- ment tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007;7:10.
4. Hanley DA, Cranney A, Jones G, et al. Vitamin D in adult health and disease: a review and guideline statement from osteoporosis Canada. CMAJ 2010. DOI 10.1503/cmaj.080663.
5. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81.
6. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008;88:582S-6S.
7. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004;89:5387-91.
8. Binkley N, Krueger D, Cowgill CS, et al. Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab 2004;89: 3152-7.
9. Jones G, Horst R, Carter G, et al. Contemporary diagnosis and treatment of vita- min D-related disorders. J Bone Miner Res 2007;22(Suppl 2):V11-5.
10. Lips P, Chapuy MC, Dawson-Hughes B, et al. An international comparison of serum 25-hydroxyvitamin D measurements. Osteoporos Int 1999;9:394-7.
11. Heaney RP, Davies KM, Chen TC, et al. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003;77:204-10.
12. Bacon CJ, Gamble GD, Horne AM, et al. A comparison of three high dose oral vit- amin D3 supplementation regimens. J Bone Miner Res 2007;22(Suppl 1):S126.
13. Gaugris S, Heaney RP, Boonen S, et al. Vitamin D inadequacy among post-menopausal women: a systematic review. QJM 2005;98:667-76.
14. Weatherall M. A meta-analysis of 25 hydroxyvitamin D in older people with frac- ture of the proximal femur. N Z Med J 2000;113:137-40.
15. Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D suffi- ciency: implications for establishing a new effective dietary intake recommenda- tion for vitamin D. J Nutr 2005;135:317-22.
16. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune dis- eases, cancers, and cardiovascular disease. Am J Clin Nutr 2004;80(Suppl):1678S-88S.
17. Roth DE, Martz P, Yeo R, et al. Are national vitamin D guidelines sufficient to maintain adequate blood levels in children? Can J Public Health 2005;96:443-9.
18. Rucker D, Allan JA, Fick GH, et al. Vitamin D insufficiency in a population of healthy western Canadians. CMAJ 2002;166:1517-24.
19. Vieth R, Cole DE, Hawker GA, et al. Wintertime vitamin D insufficiency is com- mon in young Canadian women, and their vitamin D intake does not prevent it. Eur J Clin Nutr 2001;55:1091-7.
20. Freedman DM, Looker AC, Chang SC, et al. Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 2007;99:1594-602.
21. Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006;84:18-28.
22. Hathcock JN, Shao A, Vieth R, et al. Risk assessment for vitamin D. Am J Clin Nutr 2007;85:6-18.
23. Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al. Positive association between 25- hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 2004;116:634-9.
24. Dawson-Hughes B, Heaney RP, Holick MF, et al. Estimates of optimal vitamin D status. Osteoporos Int 2005;16:713-6.
25. Stone K, Bauer DC, Black DM, et al. Hormonal predictors of bone loss in elderly women: a prospective study. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1998;13:1167-74.
26. Meier C, Woitge HW, Witte K, et al. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open- label prospective trial. J Bone Miner Res 2004;19:1221-30.
27. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669-83.
28. Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337:670-6.
29. Chapuy MC, Pamphile R, Paris E, et al. Combined calcium and vitamin D3 supple- mentation in elderly women: confirmation of reversal of secondary hyperparathy- roidism and hip fracture risk: the Decalyos II study. Osteoporos Int 2002;13: 257-64.
30. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327:1637-42.
31. Grant AM, Avenell A, Campbell MK, et al. Oral vitamin D3 and calcium for sec- ondary prevention of low-trauma fractures in elderly people (Randomised Evalua- tion of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005;365:1621-8.
32. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vita- min D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005;293:2257-64.
33. Chung M, Balk EM, Brendel M, et al. Vitamin D and calcium: a systematic review of health outcomes. Evidence Report/Technology Assessment 183. AHRQ Publ. 07- E015. Rockville (MD): Agency for Healthcare Research and Quality; 2009.
34. Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al. Higher 25-hydroxyvitamin D con- centrations are associated with better lower-extremity function in both active and inactive persons aged ? 60 y. Am J Clin Nutr 2004;80:752-8.
35. Bischoff-Ferrari HA, Orav EJ, Dawson-Hughes B. Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized con- trolled trial. Arch Intern Med 2006;166:424-30.
36. Broe KE, Chen TC, Weinberg J, et al. A higher dose of vitamin D reduces the risk of falls in nursing home residents: a randomized, multiple-dose study. J Am Geri- atr Soc 2007;55:234-9.
37. Flicker L, MacInnis RJ, Stein MS, et al. Should older people in residential care receive vitamin D to prevent falls? Results of a randomized trial. J Am Geriatr Soc 2005;53:1881-8.
38. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls: a meta-analysis. JAMA 2004;291:1999-2006.
39. Masuda S, Jones G. Promise of vitamin D analogues in the treatment of hyperpro- liferative conditions. Mol Cancer Ther 2006;5:797-808.
40. Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer pre- vention. Am J Public Health 2006;96:252-61.
41. Gorham ED, Garland CF, Garland FC, et al. Vitamin D and prevention of colorec- tal cancer. J Steroid Biochem Mol Biol 2005;97:179-94.
42. Grant WB, Garland CF. A critical review of studies on vitamin D in relation to col- orectal cancer. Nutr Cancer 2004;48:115-23.
43. Brown SJ. The role of vitamin D in multiple sclerosis. Ann Pharmacother 2006;40:1158-61.
44. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006;311:1770-3.
45. Mathieu C, Gysemans C, Giulietti A, et al. Vitamin D and diabetes. Diabetologia 2005;48:1247-57.
46. Lucas R, McMichael T, Smith W, et al. Solar ultraviolet radiation: global burden of disease from solar ultraviolet radiation. Geneva (Switzerland): World Health Organization; 2006.
47. Working Group of the Australian and New Zealand Bone and Mineral Society, Endocrine Society of Australia, Osteoporosis Australia. Vitamin D and adult bone health in Australia and New Zealand: a position statement. Med J Aust 2005;182: 281-5.
48. Webb AR. Who, what, where and when — influences on cutaneous vitamin D synthesis. Prog Biophys Mol Biol 2006;92:17-25.
49. Bischoff-Ferrari HA, Kiel DP, Dawson-Hughes B, et al. Dietary calcium and serum 25-hydroxyvitamin D status in relation to BMD among U.S. adults. J Bone Miner Res 2009;24:935-42.
50. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Prevention of nonvertebral frac- tures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med 2009;169:551-61.
51. Munger KL, Levin LI, Hollis BW, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296:2832-8.


Correspondence to: Dr. David A. Hanley, University of Calgary Health Sciences Centre, 3330 Hospital Drive NW, Calgary AB T2N 4N1; dahanley at ucalgary.ca

See any problem with this page? Report it (FINALLY WORKS)